Literature DB >> 12545248

HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.

Marianne Klemp Gjertsen1, Ingvil Saeterdal, Stein Saebøe-Larssen, Gustav Gaudernack.   

Abstract

Cytotoxic T-lymphocytes are one of the most important elements of the antitumor defense. Stimulation of cytotoxic T-lymphocytes outgrowth after immunization with mutant ras peptides is a desired goal since these cells may kill tumor cells in vivo. In this study we tested responding peripheral mononuclear cells from a patient with pancreatic adenocarcinoma who had received intradermal peptide vaccination with a mixture of 17-mer mutant ras peptides and granulocyte-macrophage colony-stimulating factor as an adjuvant. Responding peripheral T-cells were cloned by limiting dilution and several CD8(+) cytotoxic T-lymphocytes, specific for the K- RAS 12-Cys mutation were obtained. By using a panel of nonamer peptides containing the 12-Cys mutation and covering position 4-21 in the ras molecule, the 9-mer peptide which was actually recognized by the cytotoxic T-lymphocytes could be identified. HLA-A*0302 could be identified as the antigen-presenting molecule, and the amino acid sequence of the T-cell epitope carries the previously identified HLA-A*0302 binding motif. The nonamer peptide was contained within the vaccine peptide originally used for intradermal immunization of the patient. The cytotoxic T-lymphocytes were capable of killing target cells expressing HLA-A*0302 that coexpressed the K- RAS 12-Cys mutation after transfection. These data demonstrate that the peptide used for vaccination (17-mer) is processed and presented in vivo, and that generation of cytotoxic T-lymphocytes by vaccination with T-helper epitopes may be important for further development of specific immunotherapy of cancer patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12545248     DOI: 10.1007/s00109-002-0390-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  11 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

Review 2.  Mutated RAS: Targeting the "Untargetable" with T Cells.

Authors:  Praveen D Chatani; James C Yang
Journal:  Clin Cancer Res       Date:  2019-09-11       Impact factor: 12.531

3.  Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations.

Authors:  Tahseen H Nasti; Kyle J Rudemiller; J Barry Cochran; Hee Kyung Kim; Yuko Tsuruta; Naomi S Fineberg; Mohammad Athar; Craig A Elmets; Laura Timares
Journal:  J Immunol       Date:  2015-02-18       Impact factor: 5.422

4.  T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.

Authors:  Jon Amund Kyte; Gustav Gaudernack; Anne Faane; Kari Lislerud; Else Marit Inderberg; Paal Brunsvig; Steinar Aamdal; Gunnar Kvalheim; Sébastien Wälchli; Martin Pule
Journal:  Oncoimmunology       Date:  2016-10-24       Impact factor: 8.110

5.  Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054.

Authors:  Dangshe Ma; Jessica R Kirshner; Richard Tavaré; Makenzie Danton; Jason T Giurleo; Sosina Makonnen; Carlos Hickey; Tomas C Arnold; Marcus P Kelly; Fanny Fredriksson; Karina Bruestle; Aynur Hermann; Erica Ullman; Kurt H Edelmann; Terra Potocky; Drew Dudgeon; Nikunj B Bhatt; Mikhail Doubrovin; Thomas Barry; Christos A Kyratsous; Cagan Gurer; Naxin Tu; Hans Gartner; Andrew Murphy; Lynn E Macdonald; Jon Popke; Akiva Mintz; Adam Griesemer; William C Olson; Gavin Thurston
Journal:  Cancer Immunol Res       Date:  2022-10-04       Impact factor: 12.020

6.  Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

Authors:  Xiao-Zhong Guo; Zhong-Min Cui; Xu Liu
Journal:  World J Gastrointest Oncol       Date:  2013-02-15

7.  Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.

Authors:  Qiong J Wang; Zhiya Yu; Kayla Griffith; Ken-ichi Hanada; Nicholas P Restifo; James C Yang
Journal:  Cancer Immunol Res       Date:  2015-12-23       Impact factor: 11.151

8.  Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.

Authors:  Else-Marit Inderberg-Suso; Sissel Trachsel; Kari Lislerud; Anne-Marie Rasmussen; Gustav Gaudernack
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.

Authors:  Jasmin Quandt; Christoph Schlude; Michael Bartoschek; Rainer Will; Angel Cid-Arregui; Sebastian Schölch; Christoph Reissfelder; Jürgen Weitz; Martin Schneider; Stefan Wiemann; Frank Momburg; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2018-09-21       Impact factor: 8.110

10.  TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.

Authors:  Daniel H Palmer; Juan W Valle; Yuk Ting Ma; Olusola Faluyi; John P Neoptolemos; Trine Jensen Gjertsen; Berit Iversen; Jon Amund Eriksen; Anne-Sophie Møller; Anne-Kirsti Aksnes; Robert Miller; Svein Dueland
Journal:  Br J Cancer       Date:  2020-02-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.